J
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Jennifer S. Guimbellot's research focuses on cystic fibrosis (CF) and the development and application of therapies for the condition. She has investigated the use of triple combination therapy, specifically elexacaftor/tezacaftor/ivacaftor, in CF patients, including its use in lung transplant recipients and its interaction with other medications like tacrolimus. Her work also includes the quantitation of these therapies in human plasma and cellular lysates to understand drug concentrations and patient response. Guimbellot has explored the functional assessment of CFTR modulators using nasal epithelial organoids, demonstrating a correlation between organoid swelling and clinical outcomes. Additionally, her research extends to genetic correction of CFTR mutations, such as the W1282X mutation, using prime editing in induced pluripotent stem cells and derived airway epithelial cells. She also examines the outcomes of children diagnosed with CF, including those with inconclusive diagnoses or CFTR-related metabolic syndrome, and has investigated the use of electronic screening for social needs in pediatric pulmonary clinics.
Metrics
- h-index: 18
- Publications: 68
- Citations: 966
Selected Publications
-
Assessing Dietary Patterns and Composition Among Adults With Cystic Fibrosis Taking Highly Effective Modulator Therapy (2026)
-
Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches (2025)
-
Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches (2025)
-
Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches (2025)
-
EPS2.03Highly-effective CFTR modulation and lung development by age, gender, and height among children with cystic fibrosis (2025)
-
P018 Single measurement quantification and modeling of elexafactor, tezacaftor and ivacaftor in adults: overlap between full and reduced dosing (2025)
-
One- and Two-timepoint Sparse Sampling is Highly Predictive of Average Plasma Concentration of CFTR Modulators (2025)
-
Tobacco Smoke Exposure Decreases Longitudinal Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (2025)
-
Modulator Concentrations Significantly Contribute to Variability in Sweat Chloride Results After Therapy With Elexacaftor/Tezacaftor/Ivacaftor (2025)
-
Ivacaftor for Chronic Obstructive Pulmonary Disease: Results from a Phase 2, Randomized Controlled Trial (2024)
-
Literary evidence of the impact of nonbiological risk factors on CRMS/CFSPID: A scoping review (2024)
-
Association between biomarkers of tobacco smoke exposure and clinical efficacy of ivacaftor in the G551D observational trial (GOAL) (2024)
-
Differential distribution of ivacaftor and its metabolites in plasma and human airway epithelia (2024)
-
Pharmacokinetic variability of CFTR modulators from standard and alternative regimens (2024)
Collaboration Network
Top Collaborators
Kevin J. Ryan
University of Alabama at Birmingham (US)
15 shared publications
- Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosis
- Quantitation of cystic fibrosis triple combination therapy, elexacaftor/tezacaftor/ivacaftor, in human plasma and cellular lysate
- Plasma and cellular ivacaftor concentrations in patients with cystic fibrosis
- Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
- Pilot and feasibility study of dietary composition with elexacaftor‐tezacaftor‐ivacaftor concentrations in people with cystic fibrosis
Showing 5 of 15 shared publications
A. Chalamalla
University of Alabama at Birmingham
14 shared publications
In database
- Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
- Pilot and feasibility study of dietary composition with elexacaftor‐tezacaftor‐ivacaftor concentrations in people with cystic fibrosis
- Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with concurrent tacrolimus administration after lung transplant
- 425 Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
- Elexacaftor/Tezacaftor/Ivacaftor (ETI) in Combination With Tacrolimus After Lung Transplant
Showing 5 of 14 shared publications
Edward P. Acosta
University of Alabama at Birmingham Hospital (US)
12 shared publications
- Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosis
- Quantitation of cystic fibrosis triple combination therapy, elexacaftor/tezacaftor/ivacaftor, in human plasma and cellular lysate
- Plasma and cellular ivacaftor concentrations in patients with cystic fibrosis
- Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
- Ivacaftor for Chronic Obstructive Pulmonary Disease: Results from a Phase 2, Randomized Controlled Trial
Showing 5 of 12 shared publications
Justin D. Anderson
University of Alabama at Birmingham (US)
11 shared publications
- CFTR function and clinical response to modulators parallel nasal epithelial organoid swelling
- Quantitation of cystic fibrosis triple combination therapy, elexacaftor/tezacaftor/ivacaftor, in human plasma and cellular lysate
- Prime editing-mediated correction of the CFTR W1282X mutation in iPSCs and derived airway epithelial cells
- Plasma and cellular ivacaftor concentrations in patients with cystic fibrosis
- Pharmacogenetic actionability and medication prescribing in people with cystic fibrosis
Showing 5 of 11 shared publications
Elizabeth Baker
University of Alabama at Birmingham (US)
11 shared publications
- Outcomes of children with cystic fibrosis screen positive, inconclusive diagnosis/CFTR related metabolic syndrome
- Electronic screening for unmet social needs in a pediatric pulmonary clinic: Acceptability and associations with health outcomes
- Association between biomarkers of tobacco smoke exposure and clinical efficacy of ivacaftor in the G551D observational trial (GOAL)
- Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with concurrent tacrolimus administration after lung transplant
- Tobacco smoke exposure is associated with diminished longitudinal benefit of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis
Showing 5 of 11 shared publications
Kathleen J. Ramos
University of Washington (US)
6 shared publications
- Use of elexacaftor/tezacaftor/ivacaftor among cystic fibrosis lung transplant recipients
- Patient perspectives on elexacaftor/tezacaftor/ivacaftor after lung transplant
- Elexacaftor/Tezacaftor/Ivacaftor (ETI) in Combination With Tacrolimus After Lung Transplant
- Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches
- Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches
Showing 5 of 6 shared publications
Steven M. Rowe
Cystic Fibrosis Foundation (US)
6 shared publications
- Prime editing-mediated correction of the CFTR W1282X mutation in iPSCs and derived airway epithelial cells
- Plasma and cellular ivacaftor concentrations in patients with cystic fibrosis
- Ivacaftor for Chronic Obstructive Pulmonary Disease: Results from a Phase 2, Randomized Controlled Trial
- Association between biomarkers of tobacco smoke exposure and clinical efficacy of ivacaftor in the G551D observational trial (GOAL)
- Ivacaftor for Chronic Obstructive Pulmonary Disease- Results From a Phase 2, Randomized Controlled Trial
Showing 5 of 6 shared publications
Gabriela R. Oates
University of Alabama at Birmingham (US)
6 shared publications
- Electronic screening for unmet social needs in a pediatric pulmonary clinic: Acceptability and associations with health outcomes
- Mobile health platform for self-management of pediatric cystic fibrosis: Impact on patient-centered care outcomes
- Association between biomarkers of tobacco smoke exposure and clinical efficacy of ivacaftor in the G551D observational trial (GOAL)
- Tobacco smoke exposure is associated with diminished longitudinal benefit of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis
- 606 Social determinants of overweight and obesity in children with cystic fibrosis in the United States: a longitudinal analysis of Cystic Fibrosis Foundation Patient Registry data (2009-2019)
Showing 5 of 6 shared publications
Natalie R. Rose
University of Alabama at Birmingham (US)
6 shared publications
- Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
- Pilot and feasibility study of dietary composition with elexacaftor‐tezacaftor‐ivacaftor concentrations in people with cystic fibrosis
- Differential distribution of ivacaftor and its metabolites in plasma and human airway epithelia
- Literary evidence of the impact of nonbiological risk factors on CRMS/CFSPID: A scoping review
- Assessing dietary patterns and composition among adults with cystic fibrosis taking modulator therapy
Showing 5 of 6 shared publications
Saly Abouelenein
University of Arkansas for Medical Sciences (US)
6 shared publications
- Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with concurrent tacrolimus administration after lung transplant
- P018 Single measurement quantification and modeling of elexafactor, tezacaftor and ivacaftor in adults: overlap between full and reduced dosing
- Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches
- Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches
- 486 Modeling a single variable-time measurement of elexacaftor/tezacaftor/ivacaftor in adults
Showing 5 of 6 shared publications
Alexander E. Dowell
University of Alabama at Birmingham (US)
4 shared publications
- Quantitation of cystic fibrosis triple combination therapy, elexacaftor/tezacaftor/ivacaftor, in human plasma and cellular lysate
- Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
- Differential distribution of ivacaftor and its metabolites in plasma and human airway epithelia
- Evaluating the effects of ivacaftor exposure on <i>Staphylococcus aureus</i> small colony variant development and antibiotic tolerance
J Bergeron
University of Alabama at Birmingham (US)
4 shared publications
- Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with concurrent tacrolimus administration after lung transplant
- 425 Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
- Elexacaftor/Tezacaftor/Ivacaftor (ETI) in Combination With Tacrolimus After Lung Transplant
- 865 Elexacaftor/tezacaftor/ivacaftor concentrations are similar in transplanted and non-transplanted people with CF
Zhongyu Liu
University of Alabama at Birmingham (US)
3 shared publications
- CFTR function and clinical response to modulators parallel nasal epithelial organoid swelling
- Quantitation of cystic fibrosis triple combination therapy, elexacaftor/tezacaftor/ivacaftor, in human plasma and cellular lysate
- Prime editing-mediated correction of the CFTR W1282X mutation in iPSCs and derived airway epithelial cells
Hector Gutierrez
University of Alabama at Birmingham (US)
3 shared publications
- Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosis
- Outcomes of children with cystic fibrosis screen positive, inconclusive diagnosis/CFTR related metabolic syndrome
- Mobile health platform for self-management of pediatric cystic fibrosis: Impact on patient-centered care outcomes
William T. Harris
3 shared publications
- Association between biomarkers of tobacco smoke exposure and clinical efficacy of ivacaftor in the G551D observational trial (GOAL)
- Tobacco smoke exposure is associated with diminished longitudinal benefit of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis
- 602: Antisense oligonucleotide target site blockade of miR-145 binding selectively enhances CFTR correction in airway epithelial cells and nasal organoids
Similar Researchers
Based on overlapping research topics
Felicia Allard
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Molecular Biology Techniques and Applications
Disease Mechanisms Research
Han M
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Drug Transport and Resistance Mechanisms
Molecular Biology Techniques and Applications
Benjamin Davis
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Molecular Biology Techniques and Applications
Disease Mechanisms Research
Eniya Beemarajan
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Child and Adolescent Health
Disease Mechanisms Research
Aravindhan Veerapandiyan
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Molecular Biology Techniques and Applications
Child and Adolescent Health
Bridgett Knox
National Center for Toxicological Research
Metabolism and Genetic Disorders
Molecular Biology Techniques and Applications
Disease Mechanisms Research